Format

Send to

Choose Destination
Clin Infect Dis. 2019 May 30;68(12):2135-2143. doi: 10.1093/cid/ciy920.

Effectiveness of 13-Valent Pneumococcal Conjugate Vaccine Against Invasive Disease Caused by Serotype 3 in Children: A Systematic Review and Meta-analysis of Observational Studies.

Author information

1
Vaccines Medical Development and Scientific and Clinical Affairs, Pfizer, Inc., Collegeville, Pennsylvania.
2
Department of Social and Preventive Medicine, Laval University, Quebec City, Canada.
3
Vaccines Medical Development and Scientific and Clinical Affairs, Pfizer Canada, Inc., Kirkland, Quebec.
4
Boston University Schools of Medicine and Public Health, Massachusetts.
5
Boston Medical Center, Massachusetts.
6
Vaccines Medical Development and Scientific and Clinical Affairs, Pfizer, Inc., Paris, France.
7
Vaccines Medical Development and Scientific and Clinical Affairs, Pfizer, Inc., New York, New York.

Abstract

The 13-valent pneumococcal conjugate vaccine (PCV13) is the only licensed PCV with serotype 3 polysaccharide in its formulation. Postlicensure PCV13 effectiveness studies against serotype 3 invasive pneumococcal disease (IPD) in children have shown inconsistent results.  We performed a systematic review and meta-analysis of observational studies to assess PCV13 vaccine effectiveness (VE) for serotype 3 IPD in children. We systematically searched PubMed, Embase, and the Cochrane library for studies published before 14 August 2017. We identified 4 published studies and 2 conference posters that provided PCV13 VE estimates stratified by serotype. The pooled PCV13 VE against serotype 3 IPD from the random-effects meta-analysis was 63.5% (95% confidence interval [CI], 37.3%-89.7%). A sensitivity analysis including conference posters gave a pooled VE estimate of 72.4% (95% CI, 56.7%-88.0%). The pooled data from case-control studies with similar methodologies and high quality support direct PCV13 protection against serotype 3 IPD in children.

KEYWORDS:

meta-analysis; pneumococcal conjugate vaccine; serotype 3

Supplemental Content

Full text links

Icon for Silverchair Information Systems Icon for PubMed Central
Loading ...
Support Center